Use of von Willebrand factor (vWF) -containing concentrates as therapeutic agents for use in combination with antithrombotic and fibrinolytic therapies

摘要

The present invention relates to the administration of von Willebrand factor (vWF) -containing drugs in connection with the use of blood anticoagulants alone as a therapeutic or in combination with fibrin lysate. The patient may be administered concurrently with or after anticoagulant treatment and lysis treatment for the purpose of reducing the risk of bleeding. The principle of treatment is to separate anticoagulant and / or fibrin lysis, which is a desirable effect during treatment, from undesirable bleeding.